Skip to content

Safety and Efficacy of Carbone Dioxide (CO2) Laser System in Treatment of Female Stress Urinary Incontinence.

Prospective, Open-Label, Multi-Center, Non- Comparative Study to Assess the Safety and Efficacy of CO2 Laser System (FemiLiftTM) in the Treatment of Stress Urinary Incontinence (SUI) in Female Subjects.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02981654
Acronym
CO2
Enrollment
60
Registered
2016-12-05
Start date
2016-12-31
Completion date
2018-05-31
Last updated
2016-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Stress Urinary Incontinence

Brief summary

This is a prospective, open-label, multi-center, non-comparative study that will be conducted on female subjects between 30 and 75 years of age, diagnosed with stress urinary incontinence (SUI). Following the screening period, including urodynamic assessment to confirm SUI, each subject will undergo three FemiLiftTM treatment sessions, and will be followed up for a period of one year. The main efficacy endpoint in this study is defined as significant improvement (score of 6 or 7) in the urinary incontinence measured with PGI-I score at the 6 months visit. Various subjective and objective measures of incontinence severity, quality of life, sexual function and tissue effects will be performed at follow up.

Detailed description

Improvement in SUI symptoms as measured by the following parameters: Objective parameters: * Change from baseline in 3 days Urinary Diary - at 1, 2, 6 and 12 months: * Number of incontinence episodes per day * Number of pads used per day * Change from baseline in 1 hour pad test 1, 2, 6 and 12 months * Change from baseline as assessed with Vaginal Biopsy Subjective parameters: * Patient Global Impression of Severity (PGI-S) - 4-point Likert scale - at screening, 1, 2, 6 and 12 months * Change from baseline in Pelvic Floor Distress Inventory Questionnaire (PFDI) - at 1, 2, 6 and 12 months * Change from baseline in Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ) - at 1, 2, 6 and 12 months * Change from baseline in Pelvic Floor Impact Questionnaire (PFIQ) - at 1, 2, 6 and 12 months

Interventions

DEVICEAlma Lasers Pixel carbon dioxide laser system

The vaginal handpiece sheath is lubricated with baby oil. Set the initial energy level (startup set up recommendations: High mode, 40 millijoule/pixel; according to the patient reaction you can increase up to 120 max. Pulse mode or Repeat mode). The handpiece is inserted as distally as possible, with the laser energy's window oriented to the 12:00 o'clock position. There are position markings on the handpiece. Trigger a laser pulse by pressing the footswitch. Shoot the laser and rotate the probe by one hour at a time. When you reach the 12:00 o'clock position again, withdrawal the headpiece back by one centimeter and repeat the rotational treatment process.

Sponsors

The Baruch Padeh Medical Center, Poriya
CollaboratorOTHER_GOV
Kaplan Medical Center
CollaboratorOTHER
Sheba Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Females between 30 and 75 years of age * Provided written Informed Consent * Patients with mild to moderate stress urinary incontinence (SUI) \[according to the severity index developed by Sandvik\] * Patients with mixed urinary incontinence, while the predominant symptoms are stress related, may also be enrolled * Normal Papanicolaou smear (up to 1 year prior to screening) * Negative urine culture * Vaginal canal, introitus and vestibule free of injuries and bleeding * Positive urinary stress test (Urine leakage is demonstrated while the patient is examined with full bladder in lithotomy position, and asked to perform 3 strong coughs).

Exclusion criteria

* Positive pregnancy test * Planned pregnancy within the next year * Severe prolapse (POP\>= grade 3) * Use of photosensitive drugs * Injury or/and active infection in the treatment area * Active vaginal infection * human papillomavirus/herpes simplex virus * Undiagnosed vaginal bleeding * Urge or overflow incontinence * Patients who are on antidepressants, or α-adrenergic and anticholinergic medications * Patients with immune system diseases. * Patients with allergic reaction to laser. * Patient under treatment with photosensitivity side effects medication. * Obese women (BMI \>30) * Patient unable to follow post treatment instructions.

Design outcomes

Primary

MeasureTime frameDescription
Success Rate - SUI Symptom Improvement6 monthsSuccess rate - defined as an improvement in SUI symptoms as a score or 6 or 7 measured by the Patient Global Impression of Improvement (PGI-I) - 7-point Likert scale - at the 6 months visit

Secondary

MeasureTime frameDescription
1 hour pad test12 monthsChange from baseline in 1 hour pad test at 1, 2, 6 and 12 months post first treatment
Vaginal Biopsy12 monthsSample will be obtained from the vaginal mucosa 2 cm inside the introitus on the lateral vaginal wall.
PGI-S12 monthsChange from baseline in Patient Global Impression of Severity (PGI-S) over time
Urinary Diary12 monthsChange from baseline in 3 days Urinary Diary - at 1, 2, 6 and 12 months post first treatment: * Number of incontinence episodes per day
PISQ12 monthsChange from baseline in Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ) over time
PFIQ12 monthsChange from baseline in Pelvic Floor Impact Questionnaire (PFIQ) over time
Safety Endpoint assessed by the rate of serious device related adverse events12 monthsThe rate of serious device related adverse events reported during the study
PFDI12 monthsChange from baseline in Pelvic Floor Distress Inventory Questionnaire (PFDI) over time

Contacts

Primary ContactYair Leopld
Yair.Leopold@almasurgical.com972-54-4847271

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026